Sarepta Therapeutics (SRPT) Long-Term Deferred Tax (2012 - 2013)
Sarepta Therapeutics' (SRPT) quarterly Long-Term Deferred Tax came in at $133.6 million in Q4 2013, up 17.09% year-on-year from $114.1 million in Q4 2012, and up 17.09% quarter-over-quarter from $114.1 million in Q4 2012.
Sarepta Therapeutics (SRPT) Long-Term Deferred Tax (2012 - 2013) Analysis & Trends
Sarepta Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $133.6 million for Q4 2013.
- On a quarterly basis, Long-Term Deferred Tax rose 17.09% year-over-year to $133.6 million in Q4 2013; TTM through Dec 2013 was $133.6 million, a 17.09% increase from a year earlier, with the FY2013 full-year figure at $133.6 million, up 17.09% from the prior year.
- Long-Term Deferred Tax grew to $133.6 million in Q4 2013 per SRPT's latest filing, from $114.1 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $133.6 million in Q4 2013 and bottomed at $114.1 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Sarepta Therapeutics | 1.69 Bn | 1.28 Bn | 622.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 133.60 Mn |
| Dec 31, 2012 | 114.10 Mn |